TLR9 and neoplasm: Upon the treatment, TLR9-expressing myeloid cells (in particular, PMN-MDSC) displayed a decreased immunosuppressive activity, whereas TLR9-positive tumor cells lost the resistance to apoptosis via the STAT3 signaling (79, 80).